Traders Purchase Large Volume of Put Options on Boston Scientific (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) was the recipient of unusually large options trading activity on Monday. Stock investors purchased 23,040 put options on the stock. This represents an increase of approximately 27% compared to the typical daily volume of 18,181 put options.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.50% of the stock is owned by company insiders.

Institutional Trading of Boston Scientific

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. FWL Investment Management LLC purchased a new stake in Boston Scientific in the 2nd quarter worth approximately $26,000. Steph & Co. purchased a new stake in shares of Boston Scientific in the third quarter worth $25,000. Murphy & Mullick Capital Management Corp raised its position in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the period. Financial Consulate Inc. purchased a new position in shares of Boston Scientific during the 3rd quarter valued at $25,000. Finally, Swiss RE Ltd. bought a new position in Boston Scientific in the 4th quarter worth $26,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 0.7%

Shares of NYSE:BSX opened at $71.88 on Tuesday. Boston Scientific has a 52-week low of $69.52 and a 52-week high of $109.50. The stock has a market capitalization of $106.66 billion, a price-to-earnings ratio of 37.05, a PEG ratio of 1.00 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The stock’s 50-day simple moving average is $84.55 and its two-hundred day simple moving average is $94.24.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the prior year, the business earned $0.70 EPS. The business’s quarterly revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts expect that Boston Scientific will post 2.85 EPS for the current year.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Company actions that may support the share price: Boston Scientific negotiated a new $3.0 billion revolving credit facility (matures 2031), expanded its share‑repurchase authorization to $5.0 billion, and added two senior healthcare/finance leaders to the board — moves that can bolster liquidity and signal confidence in capital returns. Is Boston Scientific (BSX) Balancing Buybacks and Litigation or Masking Deeper Electrophysiology Risks?
• Neutral Sentiment: Options activity: traders bought ~23,040 put contracts on Monday — roughly a 27% increase vs. typical daily put volume — indicating elevated hedging or bearish interest but not a definitive directional signal by itself.
• Negative Sentiment: Legal and regulatory risk escalating: multiple law firms (Rosen, Levi & Korsinsky, Robbins, Bronstein, Schall, Faruqi & Faruqi) have filed or announced investigations and class actions on behalf of BSX investors covering the July 23, 2025–Feb 3, 2026 period; lead‑plaintiff deadlines have been set (May 4, 2026 in several notices). The suits and media coverage cite a Class I recall of the AXIOS Stent & Delivery System, a federal probe of disclosures/product safety, and allegations of misleading statements about the U.S. electrophysiology business — risks that could lead to settlements, fines, or reputational damage and weigh on earnings and cash flow. Shareholders of Boston Scientific Corporation Should Contact Levi & Korsinsky Boston Scientific Recall And Lawsuits Test Earnings Power And Capital Plans

Analyst Ratings Changes

BSX has been the topic of several recent analyst reports. Barclays cut their target price on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 3rd. JPMorgan Chase & Co. dropped their price objective on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Argus raised Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Truist Financial lowered their target price on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Finally, Mizuho reduced their price target on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $108.36.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.